Alexandre A. Barros

Dr. Alexandre A. Barros

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in The Journal of Supercritical Fluids
Verified
Journal Article
Closed access
SQSakeena Quraishi
Sakeena Quraishi
MMMarta De Jesus Oliveira Martins
Marta De Jesus Oliveira Martins
ABAlexandre A. Barros
Alexandre A. Barros
Pavel GurikovPavel Gurikov
Pavel Gurikov
SRS.P. Raman
S.P. Raman
RRRui M. Reis
Rui M. Reis

2 November 2022 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
Kardelen EcevitKardelen Ecevit
Kardelen Ecevit
ABAlexandre A. Barros
Alexandre A. Barros
Joana SilvaJoana Silva
Joana Silva
RRRui M. Reis
Rui M. Reis
The struggle between humans and pathogens has taken and is continuing to take countless lives every year. As the misusage of conventional antibiotics increases, the complexity associated with the resistance mechanisms of pathogens has been evolving into gradually more clever mechanisms, diminishing the effectiveness of antibiotics. Hence, there is a growing interest in discovering novel and reliable therapeutics able to struggle with the infection, circumvent the resistance and defend the natural microbiome. In this regard, nature-derived phenolic compounds are gaining considerable attention due to their potential safety and therapeutic effect. Phenolic compounds comprise numerous and widely distributed groups with different biological activities attributed mainly to their structure. Investigations have revealed that phenolic compounds from natural sources exhibit potent antimicrobial activity against various clinically relevant pathogens associated with microbial infection and sensitize multi-drug resistance strains to bactericidal or bacteriostatic antibiotics. This review outlines the current knowledge about the antimicrobial activity of phenolic compounds from various natural sources, with a particular focus on the structure-activity relationship and mechanisms of actions of each class of natural phenolic compounds, including simple phenols, phenolic acids, coumarin, flavonoids, tannins, stilbenes, lignans, quinones, and curcuminoids.

1 November 2015 in The Journal of Supercritical Fluids
Verified
Journal Article
Closed access
MMMarta De Jesus Oliveira Martins
Marta De Jesus Oliveira Martins
ABAlexandre A. Barros
Alexandre A. Barros
SQSakeena Quraishi
Sakeena Quraishi
Pavel GurikovPavel Gurikov
Pavel Gurikov
SRS.P. Raman
S.P. Raman
RRRui M. Reis
Rui M. Reis

16 June 2016 in Industrial & Engineering Chemistry Research
Verified
Journal Article
Closed access
João C. SilvaJoão C. Silva
João C. Silva
ABAlexandre A. Barros
Alexandre A. Barros
IAIvo M. Aroso
Ivo M. Aroso
DFDario Fassini
Dario Fassini
Tiago H. SilvaTiago H. Silva
Tiago H. Silva
ADAna Rita C. Duarte
Ana Rita C. Duarte

18 March 2019 in Macromolecular Bioscience
Verified
Journal Article
Open access
PDF file
MRMadeleine Ramstedt
Madeleine Ramstedt
Isabel RibeiroIsabel Ribeiro
Isabel Ribeiro
Helena BujdákováHelena Bujdáková
Helena Bujdáková
FMFilipe José Mergulhão
Filipe José Mergulhão
LJLuisa Jordao
Luisa Jordao
JSJelmer Sjollema
Jelmer Sjollema
In Europe, the mean incidence of urinary tract infections in intensive care units is 1.1 per 1000 patient‐days. Of these cases, catheter‐associated urinary tract infections (CAUTI) account for 98%. In total, CAUTI in hospitals is estimated to give additional health‐care costs of £1–2.5 billion in the United Kingdom alone. This is in sharp contrast to the low cost of urinary catheters and emphasizes the need for innovative products that reduce the incidence rate of CAUTI. Ureteral stents and other urinary‐tract devices suffer similar problems. Antimicrobial strategies are being developed, however, the evaluation of their efficacy is very challenging. This review aims to provide considerations and recommendations covering all relevant aspects of antimicrobial material testing, including surface characterization, biocompatibility, cytotoxicity, in vitro and in vivo tests, microbial strain selection, and hydrodynamic conditions, all in the perspective of complying to the complex pathology of device‐associated urinary tract infection. The recommendations should be on the basis of standard assays to be developed which would enable comparisons of results obtained in different research labs both in industry and in academia, as well as provide industry and academia with tools to assess the antimicrobial properties for urinary tract devices in a reliable way.

1 November 2013 in Acta Biomaterialia
Verified
Journal Article
Closed access
ABAlexandre A. Barros
Alexandre A. Barros
AAA. Alves
A. Alves
Cláudia NunesCláudia Nunes
Cláudia Nunes
Manuel A. CoimbraManuel A. Coimbra
Manuel A. Coimbra
RPR.A. Pires
R.A. Pires
RRRui M. Reis
Rui M. Reis